<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="790" width="595">
	<fontspec id="0" size="8" family="VbcfmpMyriadPro" color="#000000"/>
	<fontspec id="1" size="8" family="QpgswxMyriadPro-It" color="#000000"/>
	<fontspec id="2" size="9" family="BsfmqnMyriadPro-Semibold" color="#000000"/>
	<fontspec id="3" size="10" family="DvpphkWarnockPro" color="#000000"/>
	<fontspec id="4" size="10" family="DvpphkWarnockPro" color="#0000ff"/>
	<fontspec id="5" size="9" family="WythjnMyriadPro-SemiboldIt" color="#000000"/>
	<fontspec id="6" size="10" family="RxkldhWarnockPro-Light" color="#000000"/>
	<fontspec id="7" size="10" family="XxfdmdWarnockPro-LightIt" color="#000000"/>
	<fontspec id="8" size="10" family="RxkldhWarnockPro-Light" color="#0000ff"/>
	<fontspec id="9" size="7" family="RxkldhWarnockPro-Light" color="#000000"/>
<text top="32" left="498" width="41" height="10" font="0">Page 8 of 18</text>
<text top="32" left="57" width="34" height="10" font="0">Bousquet </text>
<text top="32" left="90" width="113" height="10" font="1"><i>et al. Clin Transl Allergy  (2016) 6:29 </i></text>
<text top="87" left="57" width="181" height="11" font="2"><b>Classification of good practices for replication</b></text>
<text top="98" left="57" width="239" height="13" font="3">Feasibility has been reviewed for the Finnish Asthma </text>
<text top="110" left="57" width="48" height="13" font="3">Plan (Ta<a href="">ble </a></text>
<text top="110" left="105" width="5" height="13" font="4"><a href="">6</a></text>
<text top="110" left="110" width="180" height="13" font="3">). It is expected that AIRWAYS ICPs follow-</text>
<text top="122" left="57" width="237" height="13" font="3">ing the expertise raised in ARIA and GARD will have a </text>
<text top="134" left="57" width="71" height="13" font="3">similar feasibility.</text>
<text top="159" left="57" width="148" height="11" font="2"><b>Facilitating partnership for scaling up</b></text>
<text top="171" left="57" width="71" height="11" font="5"><i><b>Collaborator’s role</b></i></text>
<text top="182" left="57" width="241" height="13" font="3">The ARIA programme includes over 300 members </text>
<text top="194" left="57" width="238" height="13" font="3">and AIRWAYS ICPs includes 445 members. The paper </text>
<text top="206" left="57" width="238" height="13" font="3">describing the AIRWAYS ICPs proposal is co-authored </text>
<text top="218" left="57" width="234" height="13" font="3">by 250 members (all stakeholders: health care profession-</text>
<text top="230" left="57" width="234" height="13" font="3">als, social carers, patients, government officers, method-</text>
<text top="242" left="57" width="60" height="13" font="3">ologists, etc<a href="">.) [</a></text>
<text top="242" left="116" width="5" height="13" font="4"><a href="">3</a></text>
<text top="242" left="121" width="172" height="13" font="3">]. All of the members are very committed </text>
<text top="254" left="57" width="237" height="13" font="3">to the implementation of AIRWAYS ICPs. National and </text>
<text top="266" left="57" width="234" height="13" font="3">regional groups have been initiated in all but 2 Euro-</text>
<text top="278" left="57" width="237" height="13" font="3">pean Union countries. In countries where health care is </text>
<text top="290" left="57" width="55" height="13" font="3">regionalised [</text>
<text top="290" left="112" width="10" height="13" font="4"><a href="">59</a></text>
<text top="290" left="122" width="147" height="13" font="3"><a href="">], man</a>y regional groups are in place.</text>
<text top="315" left="57" width="96" height="11" font="5"><i><b>Role of scientific societies</b></i></text>
<text top="326" left="57" width="237" height="13" font="3">AIRWAYS ICPs is in line with the mission and vision of </text>
<text top="338" left="57" width="238" height="13" font="3">scientific societies which aim to (1) promote research, </text>
<text top="350" left="57" width="238" height="13" font="3">(2) collect, assess and diffuse scientific information, (3) </text>
<text top="362" left="57" width="234" height="13" font="3">represent a scientific reference body for other scien-</text>
<text top="374" left="57" width="238" height="13" font="3">tific, health and political organisations and an advocate </text>
<text top="386" left="57" width="237" height="13" font="3">towards political organisation and the general public, (4) </text>
<text top="398" left="57" width="239" height="13" font="3">encourage and provide training, continuous education </text>
<text top="410" left="57" width="238" height="13" font="3">and professional development and (5) collaborate with </text>
<text top="422" left="57" width="237" height="13" font="3">patients and lay organisations in the area of their field in </text>
<text top="434" left="57" width="234" height="13" font="3">order to lead the way towards better understanding, pre-</text>
<text top="446" left="57" width="237" height="13" font="3">vention, management and eventual cure of diseases. The </text>
<text top="458" left="57" width="237" height="13" font="3">European Academy of Allergy and Clinical Immunology </text>
<text top="470" left="57" width="238" height="13" font="3">(EAACI), the European Respiratory Society (ERS), the </text>
<text top="482" left="57" width="237" height="13" font="3">European Rhinology Society (ERS), the European Union </text>
<text top="494" left="57" width="238" height="13" font="3">Geriatric Medicine Society (EUGMS), the International </text>
<text top="506" left="57" width="239" height="13" font="3">Academy of Pediatrics and the International Primary </text>
<text top="518" left="57" width="237" height="13" font="3">Care Respiratory Group (IPCRG) are the major societies </text>
<text top="530" left="57" width="237" height="13" font="3">in Europe of their respective field and are all members of </text>
<text top="542" left="57" width="236" height="13" font="3">AIRWAYS ICPs. A recent meeting on precision medicine </text>
<text top="554" left="57" width="237" height="13" font="3">in airways and allergic diseases was held at the European </text>
<text top="566" left="57" width="161" height="13" font="3">Union Parliament with these societie<a href="">s [</a></text>
<text top="566" left="217" width="10" height="13" font="4"><a href="">77</a></text>
<text top="566" left="227" width="5" height="13" font="3">, </text>
<text top="566" left="232" width="10" height="13" font="4"><a href="">78</a></text>
<text top="566" left="242" width="49" height="13" font="3"><a href="">]. </a>The activ-</text>
<text top="578" left="57" width="200" height="13" font="3">ities of IPCRG are summarized in Additional file </text>
<text top="578" left="257" width="5" height="13" font="4"><a href="">1</a></text>
<text top="578" left="262" width="2" height="13" font="3"><a href="">.</a></text>
<text top="603" left="57" width="116" height="11" font="5"><i><b>Role of patient’s organisations</b></i></text>
<text top="614" left="57" width="237" height="13" font="3">The goal and rationale of patient involvement in medical </text>
<text top="626" left="57" width="237" height="13" font="3">decisions is patient empowerment. Empowered patients </text>
<text top="638" left="57" width="239" height="13" font="3">know their disease. Patient empowerment commences </text>
<text top="650" left="57" width="238" height="13" font="3">with the initial consultations at the primary care level </text>
<text top="662" left="57" width="234" height="13" font="3">encompassing discussions about the patient’s ideas, con-</text>
<text top="674" left="57" width="238" height="13" font="3">cerns and expectations coupled with patient education </text>
<text top="686" left="57" width="237" height="13" font="3">about the specific disease process, what can be done to </text>
<text top="698" left="57" width="238" height="13" font="3">ameliorate the disease and ultimately self-management. </text>
<text top="710" left="57" width="237" height="13" font="3">Patients have the skills and motivation to take good care </text>
<text top="86" left="305" width="237" height="13" font="3">in their everyday life, to adjust their treatment, and are </text>
<text top="98" left="305" width="237" height="13" font="3">prepared for new or potentially exacerbating situations. </text>
<text top="110" left="305" width="238" height="13" font="3">They are able to detect side-effects, contact healthcare </text>
<text top="122" left="305" width="239" height="13" font="3">professionals when necessary and they adhere to the </text>
<text top="134" left="305" width="239" height="13" font="3">treatment regime. Many tools support empowerment, </text>
<text top="146" left="305" width="238" height="13" font="3">shared decision making models and patient education. </text>
<text top="158" left="305" width="238" height="13" font="3">Patient empowerment should be included in the health </text>
<text top="170" left="305" width="234" height="13" font="3">care professional’s curriculum. For an optimal dissemina-</text>
<text top="182" left="305" width="234" height="13" font="3">tion of good practices, there is a need for patient involve-</text>
<text top="194" left="305" width="103" height="13" font="3">ment and empowerment.</text>
<text top="206" left="313" width="226" height="13" font="3">There are recommendations to secure patient organi-</text>
<text top="218" left="305" width="234" height="13" font="3">zation/patient involvement at national (e.g. The Neth-</text>
<text top="230" left="305" width="222" height="13" font="3">erlands ZonMW) and also at European Union level [</text>
<text top="230" left="527" width="10" height="13" font="4"><a href="">79</a></text>
<text top="230" left="536" width="5" height="13" font="3">, </text>
<text top="242" left="305" width="10" height="13" font="4"><a href="">80</a></text>
<text top="242" left="315" width="5" height="13" font="3"><a href="">].</a></text>
<text top="254" left="313" width="226" height="13" font="3">EFA (European Federation of Allergy and airways dis-</text>
<text top="266" left="305" width="234" height="13" font="3">eases patient’s association), the major patient’s organisa-</text>
<text top="278" left="305" width="238" height="13" font="3">tion for respiratory and allergic diseases in Europe, has </text>
<text top="290" left="305" width="153" height="13" font="3">been very active for AIRWAYS ICP<a href="">s [</a></text>
<text top="290" left="457" width="10" height="13" font="4"><a href="">77</a></text>
<text top="290" left="467" width="5" height="13" font="3">, </text>
<text top="290" left="472" width="10" height="13" font="4"><a href="">78</a></text>
<text top="290" left="482" width="5" height="13" font="3"><a href="">].</a></text>
<text top="315" left="305" width="102" height="11" font="5"><i><b>Diffusion of good practices</b></i></text>
<text top="326" left="305" width="204" height="13" font="3">All European Union countries should be included.</text>
<text top="338" left="313" width="231" height="13" font="3">The European Geriatric Medicine, the official organ </text>
<text top="350" left="305" width="241" height="13" font="3">of the European Union Geriatric Medicine Society </text>
<text top="362" left="305" width="237" height="13" font="3">(EUGMS), has initiated a column of the EIP on AHA to </text>
<text top="374" left="305" width="237" height="13" font="3">publish important activities of the EIP on AHA in order </text>
<text top="386" left="305" width="157" height="13" font="3">to inform the medical community [</text>
<text top="386" left="462" width="5" height="13" font="4"><a href="">2</a></text>
<text top="386" left="467" width="77" height="13" font="3"><a href="">]. S</a>everal papers </text>
<text top="398" left="305" width="120" height="13" font="3">have already been publishe<a href="">d [</a></text>
<text top="398" left="425" width="5" height="13" font="4"><a href="">2</a></text>
<text top="398" left="430" width="5" height="13" font="3">, </text>
<text top="398" left="435" width="10" height="13" font="4"><a href="">29</a></text>
<text top="398" left="444" width="5" height="13" font="3">, </text>
<text top="398" left="449" width="10" height="13" font="4"><a href="">44</a></text>
<text top="398" left="459" width="5" height="13" font="3"><a href="">, </a></text>
<text top="398" left="463" width="10" height="13" font="4"><a href="">81</a></text>
<text top="398" left="473" width="6" height="13" font="3"><a href="">–</a></text>
<text top="398" left="479" width="10" height="13" font="4"><a href="">85</a></text>
<text top="398" left="489" width="5" height="13" font="3"><a href="">].</a></text>
<text top="423" left="317" width="2" height="13" font="6">  </text>
<text top="423" left="313" width="4" height="13" font="3">•</text>
<text top="423" left="325" width="92" height="13" font="7"><i>Reference Site Network</i></text>
<text top="423" left="417" width="125" height="13" font="6">: The Reference Site Network </text>
<text top="435" left="325" width="219" height="13" font="6">is already committed to AIRWAYS-ICPs (decision </text>
<text top="447" left="325" width="157" height="13" font="6">taken during the Montpellier meeting).</text>
<text top="459" left="317" width="2" height="13" font="6">  </text>
<text top="459" left="313" width="4" height="13" font="3">•</text>
<text top="459" left="325" width="58" height="13" font="7"><i>Action Groups</i></text>
<text top="459" left="383" width="159" height="13" font="6">: Area 5 of Action Group B3 is leading </text>
<text top="471" left="325" width="66" height="13" font="6">AIRWAYS ICPs.</text>
<text top="483" left="317" width="2" height="13" font="6">  </text>
<text top="483" left="313" width="4" height="13" font="3">•</text>
<text top="483" left="325" width="212" height="13" font="7"><i>Event and dedicated scaling up/twinning sessions</i></text>
<text top="483" left="536" width="4" height="13" font="6">: </text>
<text top="495" left="325" width="186" height="13" font="6">Several events have already taken place (Table </text>
<text top="495" left="511" width="5" height="13" font="8"><a href="">7</a></text>
<text top="495" left="516" width="5" height="13" font="6"><a href="">).</a></text>
<text top="507" left="317" width="2" height="13" font="6">  </text>
<text top="507" left="313" width="4" height="13" font="3">•</text>
<text top="507" left="325" width="214" height="13" font="7"><i>Network of excellence centres in respiratory and aller-</i></text>
<text top="519" left="325" width="45" height="13" font="7"><i>gic diseases</i></text>
<text top="519" left="370" width="171" height="13" font="6">: It includes the Commitments for Action </text>
<text top="531" left="325" width="217" height="13" font="6">(EIP on AHA action Plan B3), Reference Sites of the </text>
<text top="543" left="325" width="217" height="13" font="6">EIP AHA, the Global Allergy and Asthma European </text>
<text top="555" left="325" width="59" height="13" font="6">Network (GA</text>
<text top="554" left="384" width="3" height="9" font="9">2</text>
<text top="555" left="387" width="158" height="13" font="6">LEN) and members of AIRWAYS </text>
<text top="567" left="325" width="39" height="13" font="6">ICPs. GA</text>
<text top="566" left="364" width="3" height="9" font="9">2</text>
<text top="567" left="367" width="175" height="13" font="6">LEN, a Sixth European Union Framework </text>
<text top="579" left="325" width="214" height="13" font="6">Programme for Research and Technological Devel-</text>
<text top="591" left="325" width="219" height="13" font="6">opment (FP6) Network of Excellence, was created </text>
<text top="603" left="325" width="217" height="13" font="6">in 2005 as a vehicle to ensure excellence in research </text>
<text top="615" left="325" width="218" height="13" font="6">bringing together research and clinical institutions </text>
<text top="627" left="325" width="218" height="13" font="6">to combat fragmentation in the European research </text>
<text top="639" left="325" width="179" height="13" font="6">area and to tackle allergy in it<a href="">s globality [</a></text>
<text top="639" left="504" width="10" height="13" font="8"><a href="">89</a></text>
<text top="639" left="514" width="29" height="13" font="6"><a href="">]. The </a></text>
<text top="651" left="325" width="14" height="13" font="6">GA</text>
<text top="650" left="339" width="3" height="9" font="9">2</text>
<text top="651" left="342" width="196" height="13" font="6">LEN network has benefited greatly from the vol-</text>
<text top="663" left="325" width="214" height="13" font="6">untary efforts of researchers who are strongly com-</text>
<text top="675" left="325" width="217" height="13" font="6">mitted to this model of pan-European collaboration. </text>
<text top="687" left="325" width="214" height="13" font="6">The network was organized in order to increase net-</text>
<text top="699" left="325" width="217" height="13" font="6">working for scientific and clinical projects in allergy </text>
<text top="711" left="325" width="111" height="13" font="6">and asthma around Europe.</text>
</page>
</pdf2xml>
